Attachment 2 – Ontario Cancer PET Registry Study
Ontario Cancer PET Registry
The Cancer PET Registry study provides a PET scan and tracks the outcomes of patients who meet the eligibility
criteria for specific indications. This registry study is coordinated by Hamilton Health Sciences and registry data
is being maintained by the Institute for Clinical Evaluative Sciences.
NOTE: NEW INDICATION ADDED
A new indication has been added to the Ontario Cancer PET Registry. As of December 15, 2007 FDG-PET
imaging will be funded for the evaluation of patients with potentially resectable non-small cell lung cancer
(NSCLC), based upon conventional physical exam, blood work and imaging, and histological or cytologic proof
of NSCLC. The addition of NSCLC to the Registry is an interim decision based on preliminary findings in the
ELPET (Early Lung Cancer) Study. The final recommendation regarding funding for this indication will occur
when the analysis of ELPET is complete and results reported.
With the above addition, the Ministry of Health and Long-Term Care will fund PET imaging through the Ontario
PET Registry for the following indications:
• Solitary pulmonary nodule (SPN) for which a diagnosis has not been established by fine needle aspiration
(FNA), is inaccessible to FNA or there is a contra-indication to the use of FNA to obtain cytology;
• Thyroid cancer where recurrent or persistent disease is suspected on the basis of an elevated and/or rising
thyroglobulin but standard imaging studies are negative;
• Germ cell tumours where recurrent disease is suspected on the basis of elevated tumour markers (beta HCG
and/ or alpha fetoprotein) and standard imaging tests are negative, or a mass persists after primary treatment
and surgical resection is being considered; or
• Colorectal cancer where recurrent disease is suspected on the basis of elevated or rising carcinoembryronic
antigen (CEA) during follow-up after surgical resection, but standard imaging studies are negative.